How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Dry (Atrophic) Macular Degeneration Market
- By Disease Stage: Early Dry AMD, Intermediate Dry AMD, Advanced Dry AMD
- By Treatment Type: Nutritional Supplements, Anti-oxidant Therapy, Visual Aids and Devices, Emerging Pharmacological Treatments
- By Patient Age Group: 50-64 Years, 65-74 Years, 75 Years and Above
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Early Dry AMD leads By Disease Stage at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.160 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.168 →
Full report · locked preview
Everything inside the Dry (Atrophic) Macular Degeneration Market report
A complete, evidence-based study - 11 chapters and 113 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Disease Stage 3
Treatment Type 4
Patient Age Group 3
Distribution Channel 4
Companies profiled
Novartis AG
Regeneron Pharmaceuticals Inc.
Alcon Inc.
Genentech
Inc. (Roche)
Apellis Pharmaceuticals Inc.
Santen Pharmaceutical Co. Ltd.
Iveric Bio Inc.
Ophthotech Corporation
Gyroscope Therapeutics Ltd.
Kodiak Sciences Inc.
Nanoscope Therapeutics Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Regeneron Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Alcon Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Genentech
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Inc. (Roche)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Apellis Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Santen Pharmaceutical Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Iveric Bio Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Ophthotech Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Gyroscope Therapeutics Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Kodiak Sciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Nanoscope Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Chiesi Farmaceutici S.p.A.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Bayer AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Biogen Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Acucela Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$10,239M by 2033 · 8.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Early Dry AMD66.0
- Intermediate Dry AMD13.0
- Advanced Dry AMD21.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,727M → $3,377M · 8.7%
Europe$1,204M → $2,395M · 9.0%
Asia Pacific$1,099M → $2,129M · 8.6%
Latin America$680.2M → $1,304M · 8.5%
Middle East and Africa$523.3M → $991.8M · 8.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.702026
8.722027
8.722028
8.732029
8.752030
8.772031
8.782032
8.802033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG14.8
- Regeneron Pharmaceuticals Inc.23.6
- Alcon Inc.8.4
- Genentech7.3
- Inc. (Roche)8.4
- Apellis Pharmaceuticals Inc.9.4
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Disease Stage35.4%
Treatment Type15.7%
Patient Age Group36.7%
Distribution Channel12.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.1
- Europe23.5
- Asia Pacific20.9
- Latin America12.8
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 97 | 87 | 86 | 92 | 88 | 80 | 88 |
| Regeneron Pharmaceuticals Inc. | 82 | 76 | 81 | 78 | 74 | 69 | 77 |
| Alcon Inc. | 85 | 84 | 74 | 70 | 67 | 87 | 78 |
| Genentech | 66 | 81 | 67 | 58 | 77 | 80 | 72 |
| Inc. (Roche) | 74 | 60 | 76 | 75 | 64 | 55 | 67 |
| Apellis Pharmaceuticals Inc. | 53 | 49 | 68 | 67 | 67 | 57 | 60 |
| Santen Pharmaceutical Co. Ltd. | 60 | 51 | 44 | 54 | 52 | 56 | 53 |
| Iveric Bio Inc. | 54 | 51 | 39 | 35 | 46 | 45 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Regeneron Pharmaceuticals Inc.
- Alcon Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Regeneron Pharmaceuticals Inc. | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Alcon Inc. | ◐ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Genentech | ◐ | ◐ | ✓ | − | ✓ | ✓ |
| Inc. (Roche) | ✓ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Apellis Pharmaceuticals Inc. | − | − | ✓ | ◐ | ✓ | − |
| Santen Pharmaceutical Co. Ltd. | ◐ | ◐ | ◐ | − | − | − |
| Iveric Bio Inc. | ◐ | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG88
2Alcon Inc.78
3Regeneron Pharmaceuticals Inc.77
4Genentech72
5Inc. (Roche)67
6Apellis Pharmaceuticals Inc.60
7Santen Pharmaceutical Co. Ltd.53
8Iveric Bio Inc.45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Novartis AGAlcon Inc.
Challenger3
Strong scale, closing on the leaders.
Regeneron Pharmaceuticals Inc.GenentechInc. (Roche)
Contender1
Focused players with pockets of strength.
Apellis Pharmaceuticals Inc.
Niche2
Specialists in a single segment or region.
Santen Pharmaceutical Co. Ltd.Iveric Bio Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Disease Stage in North America, then scale across Dry (Atrophic) Macular Degeneration Market — a $201M beachhead inside a $3.52B market.
Beachhead (SOM)$201Mobtainable near-term
Serviceable (SAM)$1.25Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Early Dry AMD
Best fit — highest urgency & budget in Disease Stage.
Economic buyer77 fit
Intermediate Dry AMD
Strong fit — clear ROI and a fast path to value.
End user67 fit
Advanced Dry AMD
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Disease Stage in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Patient Age Group
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel29%
Digital / self-serve18%
Marketplaces10%
Positioning & messaging
§GTM 2 · p.194 →For Disease Stage leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Dry (Atrophic) Macular Degeneration Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified23%
Evaluation12%
Closed-won5%
$9.1KCAC
$51KLTV
5.6:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Dry (Atrophic) Macular Degeneration Market is a high-growth opportunity — $2.78B by 2033, compounding at 11.3%.
TAM · 2025$1.18Btoday
TAM · 2033$2.78Bforecast
CAGR11.3%2027–2033
Cumulative$16.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.78BTotal addressable market
SAM$1.15BServiceable available market
SOM$192MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.3% CAGR
Demand compounds through 2033, outpacing GDP across Disease Stage.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Disease Stage moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.78BLarge & growingTAM by 2033 at 11.3% CAGR
$1.15BServiceable nowreachable with today’s model
$192MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.17BBear7.4% CAGR
$2.78BBase11.3% CAGR
$3.56BBull14.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Dry (Atrophic) Macular Degeneration Market — a $8.24B market by 2033. Plan: grow share from 7.9% to 15.7%.
Market size · 2033$8.24Btotal addressable
Market CAGR7.4%2027–2033
Target share15.7%from 7.9% today
Revenue ambition$1.29Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.9% | 15.7% | On track |
| Revenue | $591M | $1.29B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 37.1% | 38.7% | At risk |
| Customer retention | 84.0% | 97.0% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Disease Stage
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Type capability
A defensible second engine — invest in Treatment Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Disease Stage share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $155M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Type
- Authorise North America expansion plan
- Fund R&D program for Disease Stage leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Dry (Atrophic) Macular Degeneration Market conversation — a $7.20B market you can size, segment and defend in minutes.
Market size · 2033$7.20Btotal opportunity
Growth4.0%CAGR to 2033
Addressable buyers1,156+accounts in scope
Typical ROI5.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Disease Stage
Goal Grow share in Disease Stage
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.2×return on cost, year one
< 3 mopayback period
$55K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Novartis AGRegeneron Pharmaceuticals Inc.Alcon Inc.GenentechInc. (Roche)Apellis Pharmaceuticals Inc.Santen Pharmaceutical Co. Ltd.Iveric Bio Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Dry (Atrophic) Macular Degeneration Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Dry (Atrophic) Macular Degeneration Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Dry Aging Beef Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportDry Aging Beef Sales Market
Market size, share, segmentation and regional forecast.
$525M market · 2025 base year
View reportDry and Liquid Pea Protein Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportDry Automobile Cylinder Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportDry Bath Incubator Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportDry Battery Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportDry Blending Machine Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportDry Breaks and Quick Disconnect Couplings Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportDry Cat Food Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportDry Chemical Analyzer Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportDry Chemical Fire Extinguisher Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportDry Chemistry (Dry Test) Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.